Meeting
2011 ASCO Annual Meeting
L-asparaginase (L-ASP)-related toxicities with Erwinia L-ASP in a large compassionate-use protocol.
Authors
P. V. Plourde
EUSA Pharma, West Chester, PA
P. V. Plourde , S. Jeha , L. B. Silverman , J. B. Nachman , S. R. Rheingold , G. V. H. Dahl , E. A. Raetz , T. Mercedes , T. Corn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Leukemia/Lymphoma
Citation
J Clin Oncol 29: 2011 (suppl; abstr 9534)
Abstract #
9534
Poster Bd #
37G
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Safety of asparaginase Erwinia chrysanthemi in a compassionate-use trial: Subanalysis of the adolescent/young adult (AYA) and adult patient (Pt) population.
First Author: Paul V. Plourde
Poster
2020 ASCO Virtual Scientific Program
A phase II/III study of JZP-458 in patients with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) who are hypersensitive to E. coli-derived asparaginases.
First Author: Luke Maese
Poster
2016 ASCO Quality Care Symposium
Safety of using escalated doses of enoxaparin prophylaxis in adults with acute lymphoblastic leukemia receiving asparaginase-based intensification therapy.
First Author: Hassan Abdulmaoula Sibai
Poster
2012 ASCO Annual Meeting
Pharmacokinetic (PK) and pharmacodynamics (PD) properties of SC-PEG e. coli l-asparaginase (EZN-2285) in the treatment of patients with acute lymphoblastic leukemia (ALL): Results from Children's Oncology Group (COG) study AALL07P4.
First Author: Anne L. Angiolillo